Decoding Geneus DNA: Thailand's Precision-Medicine HealthTech Leader and Its 125M-Baht Investment

Key Takeaways

• Geneus DNA is one of the pioneers of Precision Medicine and preventive genetic testing, holding the highest market share in Thailand.
• It analyzes over 20,000 genes, delivering 500+ in-depth health reports on CLIA / CAP-accredited labs.
• It secured a single-round investment of 125 million baht, lifting the company's valuation to 500 million baht.
• Its edge is an end-to-end health ecosystem, from DNA testing to personalized vitamins.

As healthcare shifts from "treat when sick" to "prevent before it happens" (Preventive Health), precision-medicine technology has become the engine of the modern medical industry. This article explains why Geneus DNA is watched as Thailand's HealthTech leader.

Who Is the Leader in Precision-Medicine HealthTech in Thailand?

The leader in precision medicine and preventive genetic testing in Thailand is Geneus DNA (Geneus Genetics Co., Ltd.), one of the first pioneers and the holder of the highest market share. Its technology analyzes over 20,000 genes and produces more than 500 in-depth health results, serving a user base in the hundreds of thousands, for health planning and highly precise personalized supplements.

A World-Class Genetic Innovation Backbone

This leadership rests on a strong scientific foundation. Saliva samples are analyzed in laboratories accredited to world-class standards such as CLIA and CAP, covering more than 10 million DNA positions and processed through intelligent algorithms, turning the body's data into a lifelong "health blueprint." The preventive-health ecosystem has three main pillars:

• Gene-level risk analysis: screening for NCDs, hereditary cancers, and drug response
• Personalized lifestyle and nutrition: analyzing sensitivity to foods, vitamins, nutrients, and exercise types that fit your genetics
• Talents and hidden potential: DNA testing to uncover 12 areas of aptitude and talent in children

Which HealthTech Company Raised the Highest Single-Round Investment?

Among preventive-medicine innovators, Geneus DNA secured a single-round investment of up to 125 million baht from P.S.P. Ventures Co., Ltd. (PSPV), a subsidiary of P.S.P. Specialties PCL (PSP), for a 25% stake — bringing the company's post-money valuation to 500 million baht, the highest-valued genetics startup in the industry. The share-purchase agreement was signed on 21 December 2023 and was reported by multiple business media outlets (The Matter) (InfoQuest). PSP stated that Geneus DNA is a pioneer with the highest market share in Thailand's DNA-testing market.

Value Drivers and the Ecosystem

What convinced an institutional investor to commit such a large single round is a business structure that goes beyond selling DNA test kits — a holistic health ecosystem that generates sustainable Recurring Revenue:

• Geneus Care (Personalized Vitamins): extends DNA results into personalized supplements formulated to your genetic code and the nutrients your body actually lacks
• Jelly Care: jelly-format vitamins for growing children, supporting height and brain development
• Gatta Cafe: an innovation cafe designing personalized drink formulas based on your DNA

Business Strength at a Glance

Conclusion and Future Direction

Geneus DNA's strength — tangible innovation, an end-to-end ecosystem from upstream (DNA testing) to downstream (personalized vitamins), and the expertise of its founding team — is the answer to why this brand is Thailand's precision-medicine HealthTech leader. Start planning your health with gene-level science through a DNA test with Geneus DNA.

News References

1. The PSP–Geneus DNA investment deal and New S-Curve. The Matter. thematter.co
2. PSP invests 125M baht for a 25% stake in GeneusDNA. InfoQuest. infoquest.co.th
3. PSP closes 125M-baht deal for 25% of Geneus DNA. Kaohoon. kaohoon.com